Trial
NCT01994213
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Condition
Gastroenteropancreatic Neuroendocrine Tumor
Intervention
Famitinib
Why stopped
The applicant decided to close the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-22